Association between Serum Follistatin-Like Protein 1 Levels and Disease Activity in Behçet’s Disease

Abstract

Introduction This study sought to determine the serum levels of follistatin-like protein 1 (FSTL-1), a glycoprotein of mesenchymal origin shown to be involved in the pathogenesis of many inflammatory diseases, for example Behçet’s disease (BD), and to investigate its association with disease activity.

Material and Methods The study included 45 patients followed for newly diagnosed Behçet’s disease who met the 1990 International Study Group criteria for BD and a control group of 36 healthy volunteers who were age- and gender-matched. Peripheral blood samples were collected from the patients and control groups. Serum FSTL-1 levels were measured using an enzyme-linked immunosorbent assay. The disease activity was assessed using the Behçet’s Disease Current Activity Form (BDCAF).

Results A comparison of serum FSTL-1 levels in the patient and control groups found significantly higher levels of FSTL-1 in the patient group. Serum FSTL-1 levels were significantly higher in female patients compared with male patients. Female patients exhibited significantly higher BDCAF scores compared with male patients (p=0.008). Erythrocyte sedimentation rate and serum FSTL-1 levels were positively correlated.

Conclusion Serum FSTL-1 levels may play a role in the aetiopathogenesis of BD and can also be a useful biomarker for determining disease activity.

Schlüsselwörter

Follistatin-Like Protein 1 - Behçet-Krankheit - Krankheitsaktivität - Sedimentationsrate der Erythrozyten

Key words

disease activity - erythrocyte sedimentation rate - follistatin-like protein 1 - Behçet's disease

Publication History

Article published online:
19 December 2023

• References

• 1 Yurdakul S, Yazici H. Behçet’s syndrome. Best Pract Res Clin Rheumatol 2008; 22: 793-809
• 2 Yazmalar L, Batmaz I, Sarıyıldız MA. et al. Sleep quality in patients with Behcet’s disease. Int J Rheum Dis 2014; 20: 2062-2069
• 3 Mahr A, Belarbi L, Wechsler B. et al. Population-based prevalence study of Behçet’s disease: Differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008; 58: 3951-3959
• 4 Shibanuma M, Mashimo J, Mita A. et al. Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-β1-regulated genes, one of which seems to encode a follistatin-related polypeptide. Eur J Biochem 1993; 217: 13-19
• 5 Tanaka M, Ozaki S, Kawabata D. et al. Potential preventive effects of follistatin-related protein/TSC-36 on joint destruction and antagonistic modulation of its autoantibodies in rheumatoid arthritis. Int Immunol 2003; 15: 71-77
• 6 Zhou X, Xiao X, Huang T. et al. Epigenetic inactivation of follistatin-like 1 mediates tumor immune evasion in nasopharyngeal carcinoma. Oncotarget 2016; 7: 16433-16444
• 7 Shi DL, Shi GR, Xie J. et al. MicroRNA-27a inhibits cell migration and invasion of fbroblast-like synoviocytes by targeting follistatin-like protein 1 in rheumatoid arthritis. Mol Cells 2016; 39: 611-618
• 8 Chaly Y, Blair HC, Smith SM. et al. Follistatin-like protein 1 regulates chondrocyte proliferation and chondrogenic differentiation of mesenchymal stem cells. Ann Rheum Dis 2015; 74: 1467-1473
• 9 Chaly Y, Marinov AD, Oxburgh L. et al. FSTL1 promotes arthritis in mice by enhancing inflammatory cytokine/chemokine expression. Arthritis Rheum 2012; 64: 1082-1088
• 10 The International Study Group for Behcet’s disease. Evaluation of diagnostic (classification) criteria in Behcet’s disease – towards internationally agreed criteria. Br J Rheumatol 1992; 31: 299-308
• 11 Lawton G, Bhakta BB, Chamberlain MA. et al. The Behçet’s Disease Activity Index. Rheumatology 2004; 43: 73-78
• 12 Oktayoglu P, Mete N, Caglayan M. et al. Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behçet’s disease and its association with disease activity and quality of life. Scand J Clin Lab Invest 2015; 75: 106-112
• 13 Li D, Wang Y, Xu N. et al. Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis. Arthritis Res Ther 2011; 13: 17
• 14 Hassard PV, Binder SW, Nelson V. et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: a case report. Gastroenterology 2001; 120: 995-999
• 15 Bang D, Oh S, Lee K-H. et al. Influence of Sex on Patients with Behçet’s Disease in Korea. In: Zouboulis CC, ed. Adamantiades-Behçet’s Disease. Advances in Experimental Medicine and Biology. Boston, MA: Springer US; 2003: 59-63
• 16 Gorelik M, Wilson DC, Cloonan YK. et al. Plasma Follistatin-Like Protein 1 is Elevated in Kawasaki Disease and May Predict Coronary Artery Aneurysm Formation. J Pediatr 2012; 161: 116-119
• 17 Chaly Y, Hostager B, Smith S. et al. Follistatin-like protein 1 and its role in inflammation and inflammatory diseases. Immunol Res 2014; 59: 266-272
• 18 Wang Y, Li D, Xu N. et al. Follistatin-like protein 1: a serum biochemical marker reflecting the severity of joint damage in patients with osteoarthritis. Arthritis Res Ther 2011; 13: 1-11